Objective: To test the safety and efficacy of aerosolized beta-2 adrenergic agonisttherapy (Albuterol Sulfate, USP) for improving clinical outcomes in patients with acutelung injury using a placebo controlled, double blinded randomized design. Hypothesis: Beta-2 adrenergic agonist therapy will improve clinical outcomes inpatients with acute lung injury (ALI). The potential mechanisms for improved outcomesinclude a decrease in pulmonary inflammation, reduction in lung endothelial andepithelial permeability, and enhanced resolution of alveolar edema.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research and Development Contracts (N01)
Project #
N01HR56169-4-0-2
Application #
7693893
Study Section
Project Start
2005-09-30
Project End
2012-09-29
Budget Start
Budget End
Support Year
Fiscal Year
2007
Total Cost
$130,950
Indirect Cost